Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

EXTX: EXACT Therapeutics first half 2025 interim results

EXACT Therapeutics
25 September, 2025: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces its interim results
for the first half 2025.

The interim report for the first half year 2025 is also available on the
company's website: www.exact-tx.com.

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics'
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.